All the news Showing 10 of 62 articles from: Hepatocellular carcinoma (HCC)Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Direct-acting antivirals for hepatitis C not linked to higher liver cancer risk in most studies Liz Highleyman / 21 April 2017 People with hepatitis C who take treatment with direct-acting antivirals (DAAs) do not appear to have a higher risk of developing liver cancer compared to those treated with interferon, and the seemingly higher ... Statins reduce risk of decompensation for people with HCV- and HBV-related cirrhosis Michael Carter / 18 April 2017 Treatment with statins reduces the risk of decompensated liver disease for people with cirrhosis caused by hepatitis B virus (HBV) and hepatitis C virus (HCV), investigators from Taiwan report in the online edition ... Co-infection with HCV increases cancer risk for people with HIV Michael Carter / 28 March 2017 People with HIV and hepatitis C virus (HCV) co-infection have an increased risk of non-AIDS-defining cancers compared to people with HIV mono-infection, investigators from Spain report in the online edition of AIDS. Even ... HCV infection increases risk of several non-liver-related cancers in elderly people Michael Carter / 09 March 2017 Hepatitis C virus (HCV) infection is associated with a range of non-liver-related cancers, investigators from the United States report in Cancer. The study population comprised over 1.6m elderly people with cancer and ... Are people with HIV and HCV co-infection who are cured of hepatitis C with DAAs at increased risk for liver cancer? Liz Highleyman / 27 February 2017 People with HIV and hepatitis C virus (HCV) co-infection who are successfully treated for hepatitis C using interferon-free direct-acting antiviral (DAA) therapy do not appear to have an increased likelihood of developing hepatocellular ... HCV Infection Linked to Nonhepatic Cancers in the Elderly Infectious Disease Advisor / 21 February 2017 Nivolumab demonstrates good safety and promising response rates in liver cancer study Liz Highleyman / 03 January 2017 Nivolumab (Opdivo), an antibody that blocks the PD-1 receptor and restores T-cell anti-tumour activity, appeared safe and was associated with disease control and stabilisation in a phase 1/2 study of people with hepatocellular ... Liver cancer risk reduced after hepatitis C treatment, but vigilance needed for aggressive cancers in months after treatment Keith Alcorn / 14 November 2016 People who are cured of hepatitis C after a course of direct-acting antiviral (DAA) treatment do not have a higher risk of developing liver cancer (hepatocellular carcinoma), and probably have a reduced ... Diabetes is a risk factor for the development of liver cancer for people with cirrhosis successfully treated for HCV Michael Carter / 04 July 2016 Diabetes is a strong risk factor for hepatocellular carcinoma (HCC) in people with hepatitis C virus (HCV) infection who have received successful treatment for the infection, Swedish investigators report in Clinical Infectious Diseases. ... People treated for hepatitis C have unexpectedly high rate of liver cancer recurrence Liz Highleyman / 28 April 2016 Hepatitis C patients with cirrhosis who were treated with direct-acting antivirals had about twice the expected likelihood of developing hepatocellular carcinoma (HCC), with the excess risk seen in people with a previous history ... ← Prev1...23456...7Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive